UNSPSC 51434947: Hydrochlorothiazide/quinapril

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434947 Hydrochlorothiazide/quinapril, a Commodity code, represents state and local procurement of specific branded and generic pharmaceutical formulations for use in emergency medical services, hospital systems, and public health programs. State and local governments purchase this medication and related products through direct bids to municipal fire and rescue services, cooperative purchasing agreements that span multiple states, and pharmacy benefit programs operated by state health agencies. The issuing bodies include municipal purchasing departments (such as the City of Tampa), state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions.

Recent solicitation activity shows a mix of direct emergency-response procurement and broader pharmaceutical supply agreements. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, with a due date of April 8, 2026 and an estimated contract value of $40,000.00; this bid called for specific medication line items including labetalol, epinephrine, adenosine, and diltiazem vials for delivery within ten calendar days and included a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, to supply state and local government facilities across Minnesota and Oregon through three authorized wholesalers with a July 1, 2026 effective date. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs. Primary activity centers in Florida, Minnesota, and Texas, with cooperative agreements extending into Oregon and across participating multistate jurisdictions.